Diabetes Research and Clinical Practice - Volume 120 - Supplement 1 - October 2016

122 / 244

significantly correlated only with age (serpinB1: r = 0.38 p =
0.001; ANGPTL8: r = 0.48 p < 0.001), duration of diabetes
(serpinB1: r = 0.36 p = 0.002; ANGPTL8: r = 0.43 p < 0.001), and
CrCl (serpinB1: r = −0.32 p = 0.006; ANGPTL8: r = −0.49 p < 0.001).
After adjustment for age and CrCl, the correlation of serpinB1
levels with ANGPTL8 levels remained significant (r = 0.38,
p = 0.002).
Conclusion: We showed that serpinB1 levels were higher in
T2DM patients than in healthy subjects, suggesting that
serpinB1 plays a role in regulation of beta cell mass in
human. Since both serpinB1 and ANGPTL8 levels correlated
with each other and with the same parameters, both proteins
could be similarly regulated in T2DM patients.
PD-40
DPP-4 inhibitors treatment in Chinese type 2 diabetes patients:
A meta-analysis
Xiaoling CAI1*, Xueying GAO1, Wenjia YANG1, Yifei CHEN1,
Lingli ZHOU 1, Xueyao HAN1, Linong JI1. 1Peking University
People’s Hospital, China
Objective: The aim of this meta-analysis is to assess the
comprehensive clinical efficacy of DPP-4 inhibitors in Chinese
type 2 diabetes patients and to evaluate whether there is a
different response to treatment with different kinds of DPP-4
inhibitors in Chinese.
Methods: Databases were systematically searched and quali-
fying clinical studies in Chinese type 2 diabetes were included.
Results: A total of 25 studies were included in the meta-
analysis. Treatment with saxagliptin resulted in a significantly
greater change from baseline in the HbA1c levels (WMD,
− 1.34%; 95% CI, −1.43 to −1.24%); treatment with sitagliptin led
to a significantly greater change from baseline (WMD, −1.20%;
95% CI, − 1.52 to −0.88%); treatment with vildagliptin was
associated with a significantly greater change from baseline in
the HbA1c levels (WMD, −1.21%; 95% CI, −1.54 to −0.87%);
treatment with linagliptin led to a significantly greater change
from baseline (WMD, −0.73%; 95% CI, −0.86 to −0.60%) and
treatment with alogliptin also led to a significantly greater
change from baseline (WMD, −0.91%; 95% CI, −1.48 to −0.33%).
In terms of body weight, treatment with saxagliptin was
associated with no significantly decreases from baseline in
Chinese T2DM patients (WMD, − 0.17 kg, 95% CI, −4.26 to
3.92 kg). Treatment with sitagliptin and linagliptin were also
associated with no significantly changes frombaseline in body
weight (WMD, 0.03 kg and 0.11 kg respectively, p > 0.05).
Conclusions: In Chinese type 2 diabetes patients, the efficacy
of glucose control in all the five kinds of DPP-4 inhibitor
treatment is well confirmed and no significant change in body
weight is found.
PD-41
Identical hypoglycaemic effect of teneligliptin with linagliptin
in type 2 diabetes with chronic kidney disease
YoshiharuWADA 1*, Yoshiyuki HAMAMOTO2, Sachiko HONJO1,
Yukiko KAWASAKI 1, Emi OKAMURA1, Jun FUJIKAWA1,
Akihiro HAMASAKI 1. 1The Tazuke Kofukai Medical Research
Institute Kitano Hospital, 2Kansai Electric Power Hospital, Japan
Background: Since the major excretion pathway of both
teneligliptin and linagliptin is through the liver, they can be
used in regular dose in patients with severe renal dysfunction.
However, to date, there have been no studies comparing the
hypoglycaemic effect of these two drugs. Therefore, we
conducted a study to compare the effectiveness between the
two drugs in Japanese patients with chronic renal disease.
Subjects and methods: The outpatients who were adminis-
tered teneligliptin or linagliptin newly or add-on to existed
therapy were retrospectively extracted. Only those who with
HbA1c more than 7.0% and eGFR less than 60 mL/min/1.73 m2
at baseline were selected, and those patients on hemodialysis
or discontinued/changed medicine within 6 months were
excluded. The HbA1c levels, body weight and serum creatinine
levels were investigated before and 3 and 6 months after the
drug administration.
Results: A total of 34 patients (male 25; mean age: 70.0 ± 11.6 S.
D. years, BMI: 25.5 ± 4.6 kg/m2, serum creatinine: 1.5 ± 0.9 mg/
dL, HbA1c: 8.0 ± 1.0%), with 20 mg of teneligliptin (n = 13; male
10: group A) and 5mg of linagliptin (n = 21; male 15: group B)
were enrolled in the study. HbA1c levels were similarly
decreased in both groups (3 m: − 0.7 ± 0.6% vs. −1.1 ± 0.9%
P = 0.09; 6 m: −1.1 ± 1.3% vs. −1.3 ± 1.1% P = 0.52, group A vs. B,
respectively). Body weight (3 m: 0.3 ± 2.3 kg vs. 0.0 ± 0.9 kg; 6 m:
−0.1 ± 2.7 kg vs. −0.1 ± 1.2 kg) and serum creatinine levels (3 m:
−0.1 ± 0.5 mg/dL vs. 0.2 ± 0.4 mg/dL; 6m: −0.1 ± 2.7 mg/dL vs.
−0.1 ± 1.2 mg/dL) did not show any significant change in both
groups.
Conclusion: The hypoglycaemic effect of teneligliptin was
identical to linagliptin in Japanese patients with chronic
kidney disease. Either drug did not affect body weight and
kidney function during 6 months.
PD-42
The study of anti-diabetic drugs treatment (Monotherapy,
Bitherapy, and Tritherapy) among diabetic mellitus patients in
Preah Kossamak Hospital, Cambodia
Sith Dara SEA1*, Khun TOUCH2. 1International University, 2Chief
of Cambodia-Korea Diabetes Center, Preah Kossamak Hospital,
Cambodia
Objective:To evaluate utilization pattern of anti-diabetic drugs
in three different forms: Monotherapy, Bitherapy, Tritherapy
on Type II diabetic patients.
Methods: A study was carried out in 250 cases patients for a
period of one year in the Department of Diabetology at Preah
Kossamak Hospital, from 2014 to 2015. Patients treated with
anti-diabetic drugs including Monotherapy, Bitherapy,
Tritherapy. The demographic data and utilization of different
classes of anti-diabetic drugs as well as individual drugs were
analyzed.
Result: The study was shown that the popular treating option
for anti-diabetic agent was monotherapy, about 80% overall.
And the drug that was used to treat in this type of therapy was
Metformin (Biguanides). It was used the most among other
hypoglycemic drugs, and there were two kinds of Metformin
used: Metformin 500 and Metformin XR. About 75% of the
population used Metformin 500, while a smaller amount used
Metformin XR. Apart fromMonotherapy, Bitherapy of the anti-
diabetic agents was popular after that, in which it accounted
for 14%. And lastly, Tritherapy was the least popular option
among all, 7%.
Conclusion: Metformin 500 was the most commonly used
drugs, in both monotherapy and as well as bi- and tritherapy.
Overall, those two drugs were used effectively among all
patients while the other anti-diabetic drugs’ usage percen-
tages were low. Moreover, patient knowledge about their
drugs’ usage is low. In this study, the cost of drugs per
prescription was found to be very high. However, we can
reduce the cost per prescription by choosing most economical
drugs without changing its quality.
PD-45
The effect of Djulis hull on postprandial plasma glucose of
Type II diabetes patients
Wen-hui CHEN1*, Po-Hsien LI2. 1Nutrition Division of Lukang
branch of Changhua Christian Hospital (CCH), 2Department of
Medical Botanicals and Health Applications of Dayeh University,
Taiwan
Djulis (Chenopodium formosanum Koidz) is a crop that is
specific to Taiwan that is rich in dietary fiber, phenols, and
betalains. This study was aimed to determine the effect of
Poster Presentations / Diabetes Research and Clinical Practice 120S1 (2016) S65–S211 S104